ArticleFrontiers in oncology2024
Clinicopathologic and ultrasonographic features of combined hepatocellular-cholangiocarcinoma and its correlation with microvascular invasion: a predictive role of contrast-enhanced ultrasound.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to investigate the clinicopathological and ultrasonography characteristics of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and its correlation with microvascular invasion (MVI), as well as the predictive value of contrast-enhanced ultrasound (CEUS) imaging. Methods: A retrospective analysis was conducted on 57 patients diagnosed with cHCC-CCA between November 2017 and May 2023 at Guizhou Provincial People's Hospital. Among them, 27 patients were MVI-positive and 30 patients were MVI-negative, all of whom underwent preoperative CEUS within 2 weeks. Clinical data, ultrasonographic findings, and CEUS features were compared between the two groups to analyze the influencing factors and predictive value of MVI in cHCC-CCA patients. Results: Compared to the MVI-negative group, the MVI-positive group showed a higher proportion of tumors with a maximum diameter greater than 5 cm, elevated alpha-fetoprotein (AFP) levels, low echo halo around the tumor, non-smooth tumor contour, peripheral irregular rim-like enhancement and early washout (≤60s) with nodular patterns on CEUS (P<0.05). Multivariate logistic regression analysis revealed that low echo halo, peripheral irregular rim-like enhancement, and early washout were independent risk factors for MVI in cHCC-CCA patients. The receiver operating characteristic (ROC) curve analysis demonstrated an area under the curve (AUC) of 0.8056 for these factors. Conclusions: Ultrasonographic and CEUS features have a certain correlation with MVI in cHCC-CCA patients. Low echo halo, peripheral irregular rim-like enhancement, and early washout are independent risk factors for MVI in patients with cHCC-CCA. These features have a predictive value in determining the presence of MVI in patients with cHCC-CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.